John Wiley and Sons Class B shares show strong near-term price momentum with volume surging 2.7 times average, but the stock is near its 52-week high with no remaining upside to resistance and heavy research segment concentration, making the risk-reward unfavorable for new buyers.
Thesis pillars
- Strong Momentum Volume Surge↑Improving
- Upside Exhaustion Near High↑Improving
- Research Segment Concentration↑Improving
- +1 more pillar — see the Why tab for full reasoning
John Wiley & Sons, Inc. (WLYB) Stock Analysis
Communication Services · Publishing
Hold if already holding. Not a fresh buy at $50.21, but acceptable to hold if already in. Reason: Concentration risk — Product: Research segment (64.0%).
John Wiley & Sons publishes scientific, technical, and scholarly research journals and academic/professional books and courseware through its Research and Learning segments, drawing 83% of adjusted revenue from digital products in fiscal 2025. Research contributed about 64% and... Read more
Hold if already holding. Not a fresh buy at $50.21, but acceptable to hold if already in. Reason: Concentration risk — Product: Research segment (64.0%). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.4/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About John Wiley & Sons, Inc.
About John Wiley & Sons, Inc.
John Wiley & Sons publishes more than 1,800 peer-reviewed scientific, technical, and scholarly journals through its Research segment, which generated approximately 64% of fiscal 2025 consolidated revenue, while its Learning segment of academic and professional books, courseware, and assessments contributed roughly 35%. Operations span the United States, United Kingdom, Sri Lanka, Germany, and India, with about 49% of consolidated revenue earned outside the US, and 83% of adjusted revenue coming from digital products and services.
Research revenue comes from Journal Subscriptions and Transformational Agreements sold directly to research institutions and library consortia under multi-year contracts, Open Access publishing fees paid by authors or their funders, and licensing revenue that increasingly includes fees from AI developers training models on Wiley's content. Approximately 46% of Journal Subscriptions revenue derives from publication rights owned by professional societies and other partners under long-term or jointly-owned contracts, with royalties paid back to those societies. The Learning segment sells print and digital textbooks, courseware such as WileyPLUS and zyBooks, and professional assessments through bookstores, online retailers, and direct-to-student channels, distributing digital titles through intermediaries including Amazon, Apple, and Google. Wiley owns no printing facilities and has outsourced US book distribution operations to Cengage Learning, reflecting a broader shift toward variable-cost, asset-light production and distribution.
Show full overview
Wiley's Research segment carries a funding-policy dependency the 10-K flags directly: proposed reductions in US federal funding for the National Institutes of Health and Department of Education could constrain library and university customers' ability to renew journal subscriptions, even though Wiley's geographic revenue distribution provides some offsetting diversification. A separate, less-diversifiable exposure sits in content supply — approximately 30% of articles published in Research during calendar year 2024 included China-based authors, comparable to the roughly 32% industry rate, while Chinese institutions have begun compiling early-warning lists of foreign journals carrying high volumes of China-authored content, a screening practice that could constrain future submission volume from that market.
See also: Communication Services · Publishing
From John Wiley & Sons, Inc.'s most recent 10-K filing, extracted July 26, 2026.
Recent developments
updated 2026-07-27Recent Developments — John Wiley & Sons, Inc.
Latest news
- NEWS John Wiley & Sons Q4 2026 Earnings Call Transcript — benzinga Jun 17, 2026 neutral
- NEWS John Wiley & Sons Sees FY2027 Adj EPS $4.60-$5.05 vs $4.75 Est — benzinga Jun 16, 2026 neutral
- NEWS John Wiley & Sons Q4 Adj. EPS $1.67 Beats $1.65 Estimate, Sales $447.941M Miss $450.000M Estimate. — benzinga Jun 16, 2026 neutral
- NEWS Earnings Scheduled For June 16, 2026 — benzinga Jun 16, 2026 neutral
Generated 2026-07-27T17:57:53Z.
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHProductResearch segment64%10-K Item 1: 'Research revenue accounted for approximately 64% of our consolidated revenue in the year ended April 30, 2025, with a 32.1% Adjusted EBITDA margin.'
- MEDIUMGeographicoutside the US49%10-K Item 1: 'In the year ended April 30, 2025, approximately 49% of our consolidated revenue was from outside the US.'
- MEDIUMcounterpartyprofessional societies46%10-K Item 1: 'Approximately 46% of Journal Subscriptions revenue is derived from publication rights that are owned by professional societies and other publishing partners such as research institutions or foundations, and are published by us pursuant to long-term contracts or owned jointly with such entities.'
- MEDIUMGeographicChina-based authors30%10-K Item 1A: 'In our Research segment, approximately 30% of the articles we published in calendar year 2024 included China-based authors.'
Material Events(8-K, last 90d)
- 2026-05-06Item 5.02MEDIUMEVP & GM of Research and Learning Jay Flynn departed without cause; Jessica Kowalski (previously Microsoft, AWS, RELX) was appointed EVP & GM of Research effective May 11, 2026, per press release dated May 6, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $50.21, but acceptable to hold if already in. Reason: Concentration risk — Product: Research segment (64.0%). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $52.22 (+4.0%), stop $49.29 (−1.9%), A.R:R 0.0:1. Score 6.4/10, moderate confidence.
Take-profit target: $52.22 (+4.0% upside). Target $52.22 (+4.0%), stop $49.29 (−1.9%), A.R:R 0.0:1. Stop-loss: $49.29.
Concentration risk — Product: Research segment (64.0%).
John Wiley & Sons, Inc. trades at a P/E of 12.1 (forward N/A). TrendMatrix value score: 9.2/10. Verdict: Hold.
5 analysts cover WLYB with a consensus score of 4.0/5.
What does John Wiley & Sons, Inc. do?John Wiley & Sons publishes scientific, technical, and scholarly research journals and academic/professional books and...
John Wiley & Sons publishes scientific, technical, and scholarly research journals and academic/professional books and courseware through its Research and Learning segments, drawing 83% of adjusted revenue from digital products in fiscal 2025. Research contributed about 64% and Learning about 35% of consolidated revenue, primarily from institutional journal subscriptions, open-access publishing fees, and higher-education course materials, with roughly 49% of revenue earned outside the United States.